Progress in the application of JAK inhibitors in atopic dermatitis
10.3760/cma.j.cn112150-20241016-00820
- VernacularTitle:选择性Janus激酶抑制剂在特应性皮炎中的应用进展
- Author:
Wo YAO
1
;
Huiying WANG
1
Author Information
1. 浙江大学医学院附属第二医院变态反应科，杭州 310009
- Publication Type:Journal Article
- Keywords:
Atopic dermatitis;
Janus kinase;
JAK inhibitor;
Small molecule drugs;
Aboxitinib;
Upatinib
- From:
Chinese Journal of Preventive Medicine
2025;59(9):1566-1574
- CountryChina
- Language:Chinese
-
Abstract:
Atopic dermatitis is a chronic recurrent inflammatory skin disorder associated with heterogenous presentation and immense patient burden. Previous therapeutic drugs include topical glucocorticoids, topical calcineurin inhibitors, oral antihistamines, systemic immunosuppressants, glucocorticoids and biologcis, etc. In recent years, a variety of small molecule drugs have been approved for the treatment of atopic dermatitis.Two selective JAK inhibitors Upadacitinib and Abrocitinib, have been approved for AD treatment indications in China. This mini-review summarizes the clinical application of these two drugs in the treatment of AD, including the underlying molecular mechanisms, clinical trials, and clinical experiences, highlighting the value of selective JAK inhibitors in AD therapy.
